The University of Southampton
University of Southampton Institutional Repository

The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making

The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making
The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making

BACKGROUND: Neoadjuvant systemic therapy (NST) is increasingly used in the treatment of breast cancer, yet it is clear that there is significant geographical variation in its use in the UK. This study aimed to examine stated practice across UK breast units, in terms of indications for use, radiological monitoring, pathological reporting of treatment response, and post-treatment surgical management.

METHODS: Multidisciplinary teams (MDTs) from all UK breast units were invited to participate in the NeST study. A detailed questionnaire assessing current stated practice was distributed to all participating units in December 2017 and data collated securely usingREDCap. Descriptive statistics were calculated for each questionnaire item.

RESULTS: Thirty-nine MDTs from a diverse range of hospitals responded. All MDTs routinely offered neoadjuvant chemotherapy (NACT) to a median of 10% (range 5-60%) of patients. Neoadjuvant endocrine therapy (NET) was offered to a median of 4% (range 0-25%) of patients by 66% of MDTs. The principal indication given for use of neoadjuvant therapy was for surgical downstaging. There was no consensus on methods of radiological monitoring of response, and a wide variety of pathological reporting systems were used to assess tumour response. Twenty-five percent of centres reported resecting the original tumour footprint, irrespective of clinical/radiological response. Radiologically negative axillae at diagnosis routinely had post-NACT or post-NET sentinel lymph node biopsy (SLNB) in 73.0 and 84% of centres respectively, whereas 16% performed SLNB pre-NACT. Positive axillae at diagnosis would receive axillary node clearance at 60% of centres, regardless of response to NACT.

DISCUSSION: There is wide variation in the stated use of neoadjuvant systemic therapy across the UK, with general low usage of NET. Surgical downstaging remains the most common indication of the use of NAC, although not all centres leverage the benefits of NAC for de-escalating surgery to the breast and/or axilla. There is a need for agreed multidisciplinary guidance for optimising selection and management of patients for NST. These findings will be corroborated in phase II of the NeST study which is a national collaborative prospective audit of NST utilisation and clinical outcomes.

Breast cancer, Chemotherapy, Endocrine therapy, Neoadjuvant treatment, Surgery
1471-2407
90
Whitehead, I
81d89e81-8b9e-459c-b7e0-4f4fbf8023a4
Irwin, G W
069f851d-a979-409e-8eb7-b8735fe9e91d
Bannon, F
a2703bbd-5a37-451f-bf05-a7e8aff50b69
Coles, C E
89f5427d-fe39-4931-aef3-18d157911d33
Copson, E
a94cdbd6-f6e2-429d-a7c0-462c7da0e92b
Cutress, R I
68ae4f86-e8cf-411f-a335-cdba51797406
Dave, R V
f201df6c-81f9-49bf-a915-9c82629ec9d4
Gardiner, M D
eea0ad25-65ea-4867-a60c-311aac543eab
Grayson, M
f7168755-bdc5-4ee9-b434-188125a7bf76
Holcombe, C
f9196a8b-3f04-49cf-aa7b-e0a3e02caa57
Irshad, S
b8d682ca-abd4-4a57-a5c9-d2a96dfacbcf
O'Brien, C
5ff08625-7eaf-418e-a3da-f221ef529649
O'Connell, R L
69552f5b-305c-4a34-8b7d-6c5b8a42a698
Palmieri, C
42e792f2-a7ce-4461-acb2-b802bb9c012e
Shaaban, A M
8c0e9d23-e705-453e-bb5e-f34c4a303145
Sharma, N
5cb90431-b081-414c-bb16-238da0ec84e4
Singh, J K
117c4e9d-4628-405f-98d6-a97244b8f6f9
Potter, S
bfe8461d-7483-4151-820e-47dbba3e90a4
McIntosh, S A
64e6b959-5e9c-4755-a352-4554f625ec2b
NeST Study Research Collaborative
Whitehead, I
81d89e81-8b9e-459c-b7e0-4f4fbf8023a4
Irwin, G W
069f851d-a979-409e-8eb7-b8735fe9e91d
Bannon, F
a2703bbd-5a37-451f-bf05-a7e8aff50b69
Coles, C E
89f5427d-fe39-4931-aef3-18d157911d33
Copson, E
a94cdbd6-f6e2-429d-a7c0-462c7da0e92b
Cutress, R I
68ae4f86-e8cf-411f-a335-cdba51797406
Dave, R V
f201df6c-81f9-49bf-a915-9c82629ec9d4
Gardiner, M D
eea0ad25-65ea-4867-a60c-311aac543eab
Grayson, M
f7168755-bdc5-4ee9-b434-188125a7bf76
Holcombe, C
f9196a8b-3f04-49cf-aa7b-e0a3e02caa57
Irshad, S
b8d682ca-abd4-4a57-a5c9-d2a96dfacbcf
O'Brien, C
5ff08625-7eaf-418e-a3da-f221ef529649
O'Connell, R L
69552f5b-305c-4a34-8b7d-6c5b8a42a698
Palmieri, C
42e792f2-a7ce-4461-acb2-b802bb9c012e
Shaaban, A M
8c0e9d23-e705-453e-bb5e-f34c4a303145
Sharma, N
5cb90431-b081-414c-bb16-238da0ec84e4
Singh, J K
117c4e9d-4628-405f-98d6-a97244b8f6f9
Potter, S
bfe8461d-7483-4151-820e-47dbba3e90a4
McIntosh, S A
64e6b959-5e9c-4755-a352-4554f625ec2b

NeST Study Research Collaborative (2021) The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making. BMC cancer, 21 (1), 90, [90]. (doi:10.1186/s12885-020-07757-6).

Record type: Article

Abstract

BACKGROUND: Neoadjuvant systemic therapy (NST) is increasingly used in the treatment of breast cancer, yet it is clear that there is significant geographical variation in its use in the UK. This study aimed to examine stated practice across UK breast units, in terms of indications for use, radiological monitoring, pathological reporting of treatment response, and post-treatment surgical management.

METHODS: Multidisciplinary teams (MDTs) from all UK breast units were invited to participate in the NeST study. A detailed questionnaire assessing current stated practice was distributed to all participating units in December 2017 and data collated securely usingREDCap. Descriptive statistics were calculated for each questionnaire item.

RESULTS: Thirty-nine MDTs from a diverse range of hospitals responded. All MDTs routinely offered neoadjuvant chemotherapy (NACT) to a median of 10% (range 5-60%) of patients. Neoadjuvant endocrine therapy (NET) was offered to a median of 4% (range 0-25%) of patients by 66% of MDTs. The principal indication given for use of neoadjuvant therapy was for surgical downstaging. There was no consensus on methods of radiological monitoring of response, and a wide variety of pathological reporting systems were used to assess tumour response. Twenty-five percent of centres reported resecting the original tumour footprint, irrespective of clinical/radiological response. Radiologically negative axillae at diagnosis routinely had post-NACT or post-NET sentinel lymph node biopsy (SLNB) in 73.0 and 84% of centres respectively, whereas 16% performed SLNB pre-NACT. Positive axillae at diagnosis would receive axillary node clearance at 60% of centres, regardless of response to NACT.

DISCUSSION: There is wide variation in the stated use of neoadjuvant systemic therapy across the UK, with general low usage of NET. Surgical downstaging remains the most common indication of the use of NAC, although not all centres leverage the benefits of NAC for de-escalating surgery to the breast and/or axilla. There is a need for agreed multidisciplinary guidance for optimising selection and management of patients for NST. These findings will be corroborated in phase II of the NeST study which is a national collaborative prospective audit of NST utilisation and clinical outcomes.

Text
s12885-020-07757-6 - Version of Record
Available under License Creative Commons Attribution.
Download (885kB)

More information

Accepted/In Press date: 21 December 2020
Published date: 22 January 2021
Keywords: Breast cancer, Chemotherapy, Endocrine therapy, Neoadjuvant treatment, Surgery

Identifiers

Local EPrints ID: 446663
URI: http://eprints.soton.ac.uk/id/eprint/446663
ISSN: 1471-2407
PURE UUID: 740906a2-86c9-4920-a1fd-4e3a7f63dd42

Catalogue record

Date deposited: 17 Feb 2021 17:31
Last modified: 16 Mar 2024 10:51

Export record

Altmetrics

Contributors

Author: I Whitehead
Author: G W Irwin
Author: F Bannon
Author: C E Coles
Author: E Copson
Author: R I Cutress
Author: R V Dave
Author: M D Gardiner
Author: M Grayson
Author: C Holcombe
Author: S Irshad
Author: C O'Brien
Author: R L O'Connell
Author: C Palmieri
Author: A M Shaaban
Author: N Sharma
Author: J K Singh
Author: S Potter
Author: S A McIntosh
Corporate Author: NeST Study Research Collaborative

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×